Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864026 · ClinicalTrials.gov registry record · Phase 4
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
A Phase 4 study of Psoriatic Arthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06864026: Recruiting Phase 4 study of Psoriatic Arthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
NCT06864026 is a Phase 4 study of Psoriatic Arthritis and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 849-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06864026, a Phase 4 study of Psoriatic Arthritis and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Primary Outcome
The HAQ-DI is a patient-reported outcome questionnaire that is used to measure disease associated disability as an assessment of physical function. It consists of 20 questions referring to 8 domains of functioning. Participants assess their degree of difficulty when performing the activities over the past week on a 4-item ordinal scale, ranging from 0, "without any difficulty," to 3, "unable to do." The scores of each of the 8 domains are summed and divided by 8. Higher scores indicate more limi
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (20)
Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale - Avondale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler - Chandler
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff - Flagstaff
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert - Gilbert
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale - Glendale
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa - Mesa
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV - Phoenix
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City - Sun City
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson - Tucson
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast - Tucson
California
- Medvin Clinical Research - Apple Valley - Apple Valley
- Medvin Clinical Research - Covina - Covina
- Newport Huntington Medical Group - Huntington Beach
- Purushotham & Akther Kotha MD, Inc - La Mesa
- Medvin Clinical Research - Riverside - Riverside
- Rheumatology Center of San Diego - San Diego
- Providence Saint John's Medical Foundation - Santa Monica
- Medvin Clinical Research - Temecula - Temecula
- Medvin Clinical Research - Tujunga - Tujunga
- Medvin Clinical Research - Whittier - Whittier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 4 |
What NCT06864026 shows while recruiting
NCT06864026 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 849-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (76% lower).
The record links to 2 conditions, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06864026 names 20 study sites across 2 states, led by Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06864026 about?
NCT06864026 is a clinical study titled "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)". The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
What is the current status of trial NCT06864026?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2025-03-06. Estimated completion is 2027-11.
What conditions does trial NCT06864026 study?
This clinical trial studies the following conditions: Psoriatic Arthritis, Overweight or Obesity.
What interventions are being tested in trial NCT06864026?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06864026?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06864026 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06864026's enrollment target sits among peer trials
200 27th of 48 higher than 20 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
RECRUITING · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI